February 23, 2017
Recommended Topic Related To:

Kyprolis

"The immunotherapy pembrolizumab (Keytruda, Merck & Co) has been approved for use in the treatment of head and neck cancer by the US Food and Drug Administration (FDA).

This is the third cancer indication for the drug; it "...

A A A

Kyprolis

KYPROLIS®
(carfilzomib) for Intraveneous Use

DRUG DESCRIPTION

Carfilzomib is a modified tetrapeptidyl epoxide, isolated as the crystalline free base. The chemical name for carfilzomib is (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran- 2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)- 4-phenylbutanamido)-4-methylpentanamide. Carfilzomib has the following structure:

KYPROLIS® (carfilzomib) Structural Formula Illustration

Carfilzomib is a crystalline substance with a molecular weight of 719.9. The molecular formula is C40H57N5O7. Carfilzomib is practically insoluble in water and very slightly soluble in acidic conditions.

Kyprolis is a sterile, white to off-white lyophilized powder and is available as a single-dose 30 mg or 60 mg vial. Each 30 mg vial contains 30 mg of carfilzomib, 1500 mg sulfobutylether beta-cyclodextrin, and 28.9 mg anhydrous citric acid and sodium hydroxide for pH adjustment (target pH 3.5). Each 60 mg vial contains 60 mg of carfilzomib, 3000 mg sulfobutylether beta-cyclodextrin, 57.7 mg citric acid, and sodium hydroxide for pH adjustment (target pH 3.5).

Last reviewed on RxList: 12/12/2016
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.